Endometrial cancer is a highly heterogeneous radiogenomics-studied gynecologic malignancy arising from the endometrial epithelium and is one of the most common gynecological cancers. Its biology is shaped by molecular subtypes and biomarkers, including POLE mutations, microsatellite instability, and tumor mutational burden, which can be linked to imaging phenotypes in radiogenomic analyses. It is also a hormone-dependent cancer, reflecting reliance on nuclear hormone receptor signaling, including progesterone signaling. Recent literature highlights MLH1 promoter methylation-induced dMMR/MSS as a documented molecular pattern in an endometrial cancer case, and peptide-based immunotargeting has been proposed as a therapeutic strategy for gynecologic cancers including peptides. Overall, the disease remains a major cause of cancer-related illness and death, with current advances focusing on biomarker-driven classification and targeted approaches.
Radiogenomics and molecular heterogeneity
- Radiogenomics was used to correlate imaging phenotypes with molecular biomarkers in endometrial cancer, emphasizing its heterogeneity and biomarker-linked imaging signatures. (PMID:41192450)
- The radiogenomics study specifically connected imaging features with POLE mutations, microsatellite instability, and tumor mutational burden. (PMID:41192450)
- A 2026 RoFo review framed endometrial cancer as a model for tumor heterogeneity in gynecologic cancer imaging research. (PMID:41192450)
Hormone-driven disease and signaling
- Endometrial cancer was described as a hormone-dependent malignancy in the context of nuclear hormone receptor biology. (PMID:42014520)
- Therapies targeting progesterone signaling were discussed as relevant to hormone-dependent cancers, including endometrial carcinomas. (PMID:42014520)
- The 2026 CMLS review placed endometrial cancer within broader lineage plasticity in hormone-driven cancers. (PMID:42014520)
Mismatch repair and epigenetic alteration
- A case report described MLH1 promoter methylation-induced dMMR/MSS in endometrial cancer, highlighting an epigenetically driven mismatch-repair phenotype. (PMID:42001360)
- The report provides a concrete example of how promoter methylation can shape endometrial cancer molecular classification. (PMID:42001360)
Immunotargeting and therapeutic development
- Peptide-based immunotargeting was discussed as a next-generation strategy for gynecological cancers, including endometrial cancer. (PMID:41930712)
- The Translational Oncology review positioned peptides as potential immunotargeting agents for this disease area. (PMID:41930712)
- This approach reflects growing interest in targeted, biomarker-informed therapies for heterogeneous endometrial tumors. (PMID:41930712)